LC-MS/MS Data Analysis Now Available Utilizing CD Genomics’ Bioinformatics-Analysis Solution

The Product Manager at CD Genomics is pleased to announce the launch of the LC-MS/MS Data Analysis service, enabling high-performance, regulated bioanalysis of small molecules, peptides, and proteins.

New York, United States – March 1, 2023 /MarketersMEDIA/ —

Bioinformatics-Analysis is a subdivision of CD Genomics, providing reliable next-generation and third-generation high-throughput sequencing data analysis, database construction, and other related data analysis services utilizing comprehensive technology. The Product Manager at CD Genomics is pleased to announce the launch of the LC-MS/MS Data Analysis service, enabling high-performance, regulated bioanalysis of small molecules, peptides, and proteins.

Liquid chromatography coupled to mass spectrometry (LC-MS) is one of the most frequently used analytical platforms in metabolomics. LC-MS is an analytical chemistry technique that combines the physical separation capabilities of liquid chromatography (or high-performance liquid chromatography) with mass spectrometry (MS). Liquid chromatography separates mixtures into separate components, while mass spectrometry detects and analyzes the molecular mass of each component with high molecular specificity and detection sensitivity.

LC-MS can achieve the total ion chromatogram by acquiring a mass spectrum. Spectra do not provide molecular weight and structure information of unknown compounds, making it difficult for qualitative analysis. However, LC-MS/MS uses tandem mass spectrometry to access molecular ion peaks and fragment ion peaks, qualitatively and quantitatively analyzing molecules. In addition, sample identification and accurate quantitation can be further enhanced by coupling two mass analyzers in series.

LC-MS/MS can detect residual compounds in pharmaceutical and food samples, identify small organic molecules, and identify and quantify contaminants and adulterants. In addition, macromolecules such as proteins can be analyzed via protein sequencing, protein post-processing translation modification site analysis and quantitative proteomics.

Mass spectrometry is a powerful analytical tool that plays a key role in drug development by providing accurate, reliable, and timely data for successful clinical trials, disease research, drug development, and target discovery experiments. CD Genomics performs high-performance, regulated bioanalysis of small molecules, peptides, and proteins utilizing LC-MS/MS.

“Our dedicated team of LC-MS/MS experts has years of experience helping scientists with experimental projects. Our areas of expertise include new chemical entities (NCEs), carbohydrates, nucleotides, steroids, technical compounds, peptides, immunosuppressants, neurotransmitters, oligonucleotides, polymer mixtures, etc.,” commented the senior scientist of CD Genomics.

About CD Genomics

With a high-performance computing platform and a bioinformatics analysis team dominated by Ph.D. and Master’s education, CD Genomics is the second-to-none provider of bioinformatics analysis services. The company takes advantage of cutting-edge bioinformatics technologies to conduct research in genomics, transcriptomics, microorganisms, epigenetics, proteomics, metabolomics, single-cell omics, and more.

Contact Info:
Name: Kiko Garcia
Email: Send Email
Organization: CD Genomics
Website: https://bioinfo.cd-genomics.com/

Release ID: 89091150

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.